Alessandra Cesano Sells 12,150 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Alessandra Cesano sold 12,150 shares of Puma Biotechnology stock in a transaction on Friday, June 13th. The stock was sold at an average price of $3.40, for a total value of $41,310.00. Following the completion of the sale, the director now directly owns 68,850 shares of the company's stock, valued at approximately $234,090. The trade was a 15.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Puma Biotechnology Stock Performance

Shares of NASDAQ:PBYI traded down $0.21 during mid-day trading on Friday, reaching $3.19. 314,744 shares of the company traded hands, compared to its average volume of 443,070. Puma Biotechnology, Inc. has a 52 week low of $2.23 and a 52 week high of $4.13. The firm has a market cap of $158.32 million, a PE ratio of 4.14 and a beta of 1.29. The company's 50 day moving average price is $3.22 and its 200-day moving average price is $3.12. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.53 and a quick ratio of 1.43.

Analysts Set New Price Targets

A number of research firms have weighed in on PBYI. Wall Street Zen raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 target price on shares of Puma Biotechnology in a report on Friday, February 28th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its holdings in shares of Puma Biotechnology by 167.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 6,351 shares during the last quarter. Graham Capital Management L.P. bought a new position in Puma Biotechnology in the 4th quarter worth about $33,000. ProShare Advisors LLC purchased a new stake in shares of Puma Biotechnology in the 4th quarter worth $36,000. C2C Wealth Management LLC purchased a new position in Puma Biotechnology during the 4th quarter valued at about $37,000. Finally, Causeway Capital Management LLC bought a new stake in shares of Puma Biotechnology in the 1st quarter valued at about $42,000. Institutional investors own 61.29% of the company's stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.